Disease-modifying Antirheumatic
Disease-modifying Antirheumatic - Related Videos
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
0 Views •
Cited by 5 •
2016
A reverse-genetics approach to understanding gene families associated with human disease is presented, using mouse as a model system, and the subsequent mouse phenotyping schedule is described. Because mice defective in a gene of interest, HtrA2, manifested Parkinsonian symptoms, the phenotyping regimen is focused on identifying neurological defects.
05:05
A Modified Precipitation Method to Isolate Urinary Exosomes
0 Views •
Cited by 32 •
2015
This manuscript describes a protocol for isolating exosomes from human urine using a modified precipitation technique.
12:45
Testing For Genetically Modified Foods
0 Views •
2023
Source: Laboratories of Margaret Workman and Kimberly Frye - Depaul University Genetic modification of foods has been a controversial issue due to debated concerns over health and environmental safety. This experiment demonstrates technical understanding of how food DNA is genetically identified, allowing for educated decision making about the safety and potential dangers of using genetically modified organisms (GMOs) in food supplies. Polymerase Chain Reaction (PCR) is used to amplify food DNA...
06:05
Modified Radical Neck Dissection for Cervical Metastasis
0 Views •
2026
Here, we present a protocol for radical neck dissection integrating oncologic resection, cranial nerve preservation, and functional reconstruction in cervical metastasis.
17:50
Preventing the Spread of Malaria and Dengue Fever Using Genetically Modified Mosquitoes
0 Views •
Cited by 10 •
2007
In this candid interview, Anthony A. James explains how mosquito genetics can be exploited to control malaria and dengue transmission. Population replacement strategy, the idea that transgenic mosquitoes can be released into the wild to control disease transmission, is introduced as well as the concept of genetic drive and the design criterion for an effective genetic drive system. The ethical considerations of releasing genetically-modified organisms into the wild are also discussed.
FAQs
These medicines act at different points in the inflammatory and autoimmune response. Depending on the treatment group, they may suppress inflammatory signaling, reduce immune-cell activity, or alter molecular pathways involved in autoimmunity. This variety allows clinicians to address the biological drivers of disease rather than relying only on medicines that reduce pain or other symptoms.
Controlling abnormal immune and inflammatory activity can help limit the processes that cause lasting joint and tissue damage. The goal extends beyond short-term symptom relief: reducing disease progression may help preserve physical function, lower the risk of disability, and support better long-term outcomes for people with inflammatory rheumatic conditions.
These categories represent major treatment groups that influence disease-related immune activity through different types of mechanisms. Conventional agents, biologic therapies, and targeted synthetic medicines are therefore not interchangeable descriptions of one identical approach. Their grouping helps organize the available strategies according to how they affect inflammatory signaling, immune cells, or molecular pathways involved in autoimmunity.
Treatment response is judged over time rather than by a single immediate change in discomfort. Clinicians follow whether the underlying inflammatory disease is being controlled and whether progression, functional limitation, or tissue damage is being reduced. Ongoing assessment also includes attention to adverse effects, allowing the treatment approach to be managed as the patient’s course becomes clearer.
Clinicians select a suitable disease-modifying approach for the rheumatic condition, then monitor treatment response and adverse effects over time. This continuing process is important because the purpose of therapy is sustained control of disease activity and prevention of damage, not simply temporary symptom improvement. Follow-up helps assess whether the intended long-term benefits are being achieved.
Rheumatoid arthritis is a central application, but these therapies are also used for other inflammatory arthritides. Their relevance in medicine comes from addressing diseases in which immune and inflammatory processes can threaten joints or other tissues. By limiting progression, treatment may help preserve function and reduce disability across these related clinical conditions.
Important outcomes include limiting lasting joint and tissue damage, preserving physical function, reducing disability, and improving long-term disease results. These goals distinguish disease-modifying treatment from an approach focused only on immediate symptom relief. Evaluating outcomes over time helps connect control of inflammatory disease with the patient’s ability to maintain function and avoid progressive impairment.